BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States

The Official State visit by the President of the Republic of Korea marks the 70th anniversary of the U.S.-ROK alliance,which is advancing peace,stability,and prosperity for the two countries,for the Asia-Pacific region,and globally

President Yoon Suk Yeol and First Lady Kim Keon Heeof the Republic ofKorea are leading the Official State visit

BIORCHESTRA Founder,Chairman,and Chief Executive,Dr. Branden Ryu,has been invited to join the Official delegation and will meet U.S. government officials and private sector industry leaders to showcase the company's transformational biotechnology platform that is under development for Alzheimer's disease Amyotrophic Lateral Sclerosis,and Parkinson's disease

CAMBRIDGE,Mass.and DAEJEON,South Korea,April 25,2023 -- BIORCHESTRA,a biotherapeutics companyfocused on rare and degenerative diseases within the Central Nervous System (CNS),announced today that the company's Scientific Founder,and Chief Executive Officer,has been invited by the Korean Government to join the Official State visit to the U.S.

Reflecting on the significance of the official visit,Dr. Ryu commented,"I am deeply honored to join President Yoon Suk Yeol and First Lady Kim Keon Heeof the Republic ofKorea on this historic U.S. visit." "The 70th anniversary of the U.S.-ROK alliance advancing peace,the Asia-Pacific region,and the world is an important celebration," Dr. Ryu concluded.

During the Official State visit,Dr. Ryu will travel to Washington,D.C.,Boston,and New York to share development progress against significant milestones in BIORCHESTRA's degenerative diseases franchise and lead program – BMD-001 – focused on first and best-in-class therapeutics. Leveraging a proprietary brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM) platform formulated for IV administration that combines targeted cell delivery capabilities and proprietary RNA chemistries,company development results include:

Broad entry into and biodistribution across the brain,demonstrating significant disease target knockdown and related functional outcomes; and

Downstream engagement of epigenetic disease hallmarks,including amyloid β plaques,and neurofibrillary tangles.

Company-sponsored studies have demonstrated significant progress,noting broad biodistribution in the brain and noteworthy neurodegenerative disease target knockdown across multiple measures from a single IV formulation in animal models up to primates. These promising results support the acceleration of pharmacokinetics and pharmacodynamics (PK/PD) studies,with the pending release of micro-RNA scope data ahead of the company's Investigational New Drug (IND) submission.

About Brain Targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM)

BTRiNTM targets an amino acid receptor in the blood-brain barrier shared by neurons,astrocytes,and microglia. In addition to significant functional outcomes in a non-human primate study of Alzheimer's disease,BTRiNTM has been leveraged with ASO and siRNA to validate the effective knockdown of a target implicated in Amyotrophic Lateral Sclerosis and Parkinson's disease.  Ongoing company discovery and development research will leverage BTRiNTM for other underserved diseases,such as Glioblastoma multiforme,Lewy body dementia,Spinocerebellar ataxia type three,Frontotemporal dementia,Progressive supranuclear palsy. For more information,visit: www.biorchestra.com/science/our-scientific-approach

AboutBMD-001

Under development for efficient and effective IV administration targeting specific micro-RNA associated with neuroinflammation,mitochondrial dysfunction,neurodegeneration,and amyloid protein deposition in Alzheimer's disease,Amyotrophic Lateral Sclerosis,and Parkinson's disease. BMD-001 has successfully demonstrated the suppression of specific microRNA across rodent and non-human primate models,normalizing homeostatic processes,reducing amyloid and tau protein deposition,reducing neuroinflammation,and improving cognitive function. 

About BIORCHESTRA

BIORCHESTRA is a biotherapeutics company focused on rare and neurodegenerative diseases within the Central Nervous System by leveraging its proprietary Brain Targeting RNAi Nanomedicine (BTRiNTM) platform. BTRiNTM combines targeted cell delivery capabilities and proprietary RNA chemistries to develop first and best-in-class therapeutics. The company has extensive research and development and GMP manufacturing capabilities in Daejeon, South Korea,and U.S. headquarters in Cambridge,Massachusetts,U.S.A.  For more information,visit: www.biorchestra.com and follow us on Twitter @biorchestra and LinkedIn.

Safe Harbor Statement

This press release contains forward-looking statements. In addition,from time to time,our representatives or we may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events,which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance,including our financial performance and projections,revenue and earnings growth,and business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature,particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements,you should consider various factors,including our ability to change the company's direction,keep pace with new technology and evolving market needs,and the competitive environment of our business. These and other factors may cause our results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by our representatives or us may not occur,and actual events and results may differ materially and are subject to risks,uncertainties,and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement,whether due to uncertainties and assumptions,the forward-looking events discussed in this press release,and other statements made from time to time by our representatives or us might not occur.

Investor Contact:

Skyline Corporate Communications Group,LLC

Scott Powell,President

One Rockefeller Plaza,10th Floor

New York,NY 10020 USA

Office: (646) 893-5835 x2

Email: info@skylineccg.com